Glaukos Corporation

GKOSNYSEUSD
121.48 USD
0.61 (0.50%)AT CLOSE (11:59 AM EDT)
121.53
0.05 (0.04%)
POST MARKET (AS OF 08:11 PM EDT)
Post Market
AS OF 08:11 PM EDT
121.53
0.05 (0.04%)
🔴Market: CLOSED
Open?$121.10
High?$122.28
Low?$119.03
Prev. Close?$120.87
Volume?455.0K
Avg. Volume?663.1K
VWAP?$121.45
Rel. Volume?0.69x
Bid / Ask
Bid?$102.23 × 500
Ask?$126.83 × 100
Spread?$24.60
Midpoint?$114.53
Valuation & Ratios
Market Cap?7.1B
Shares Out?58.5M
Float?57.4M
Float %?98.8%
P/E Ratio?N/A
P/B Ratio?10.84
EPS?-$3.21
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?4.69Strong
Quick Ratio?4.06Strong
Cash Ratio?0.90Adequate
Debt/Equity?0.10Low
ValuationRICHLY VALUED
Score
50/100
P/E?
N/A
P/B?
10.84HIGH
P/S?
14.01HIGH
P/FCF?
N/A
EV/EBITDA?
-43.9CHEAP
EV/Sales?
13.97HIGH
Returns & Efficiency
ROE?
-28.6%WEAK
ROA?
-21.0%WEAK
Cash Flow & Enterprise
FCF?$-39062000
Enterprise Value?$7.1B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Employees
1.1K
Market Cap
7.1B
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed
2015-06-25
Address
1 GLAUKOS WAY
ALISO VIEJO, CA 92656
Phone: 949-367-9600